A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

@inproceedings{Alvarez2012ADR,
  title={A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder},
  author={Enric Alvarez and V{\'i}ctor P{\'e}rez and Marianne Dragheim and Henrik Loft and Francesc Pardo i Artigas},
  booktitle={The international journal of neuropsychopharmacology},
  year={2012}
}
The efficacy, safety, and tolerability of Lu AA21004 vs. placebo using venlafaxine XR as active reference in patients with DSM-IV-TR major depressive disorder (MDD) were evaluated. Lu AA21004 is a novel antidepressant that is a 5-HT3 and 5-HT7 receptor antagonist, 5-HT1A receptor agonist, 5-HT1B receptor partial agonist and inhibitor of the 5-HT transporter in recombinant cell lines. In this 6-wk, multi-site study, 429 patients were randomly assigned (1:1:1:1) to 5 or 10 mg Lu AA21004, placebo… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 79 CITATIONS

Vortioxetine for the treatment of major depressive disorder.

  • Expert review of clinical pharmacology
  • 2014
VIEW 29 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Multi-modality: a new approach for the treatment of major depressive disorder

  • The international journal of neuropsychopharmacology
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Vortioxetine: a review of its use in major depressive disorder.

VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats

  • Pharmacology Biochemistry and Behavior
  • 2013
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 21 Highly Influenced Citations

  • Averaged 9 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004) : a novel multimodal compound for the treatment of mood and anxiety disorders

B Bang-Andersen, T Ruhland, M Jørgensen, G Smith
  • Journal of Medicinal Chemistry
  • 2011
VIEW 2 EXCERPTS

AA21004: efficacy at low serotonin transporter occupancy at clinically effective doses – from animal studies to depressed patients

J Areberg, M Dragheim, L Brennum, TB Stensbøl
  • Poster NR7-020
  • 2009
VIEW 1 EXCERPT

Effect of food on the pharmacokinetics of Lu AA21004 in healthy volunteers

Y Wang, T Wojtkowski, A Agyemang, M-C Homery
  • Journal of Clinical Pharmacology
  • 2009
VIEW 1 EXCERPT

In vivo effects of the multi-target drug Lu AA21004: a novel potential treatment for mood disorders

A Mørk, LT Brennum, SM Fallon, AB Lassen
  • Biological Psychiatry
  • 2009
VIEW 1 EXCERPT

Lu AA 21004 : efficacy at low serotonin transporter occupancy at clinically effective doses – from animal studies to depressed patients

F Artigas, P Celada, M Laruelle, A Adell
  • Poster NR 7020 presented at the 162 nd Annual Meeting of the American Psychiatric Association
  • 2009

Similar Papers

Loading similar papers…